Q3 2024 Formycon AG Earnings Call Transcript
Key Points
- Formycon AG (XTER:FYB) achieved two FDA approvals and two positive CHMP opinions for its biosimilars, FYB202 and FYB203, in a shorter time than the industry average.
- The company successfully included the first patient in its oncology program for the Keytruda biosimilar FYB206, positioning itself among the frontrunners in this market.
- Formycon AG has launched its FYB201 Lucentis biosimilar in 20 countries, achieving a market share of over 40% in the US and even higher in the UK.
- The company is on track to launch its Stelara biosimilar FYB202 in the US by February 2025, following FDA and European Commission approvals.
- Formycon AG's financial performance is strong, with a significant increase in royalties from FYB201 and a positive impact from its equity result, reflecting successful commercialization efforts.
- Formycon AG experienced a decrease in revenue compared to 2023, attributed to reduced compensation work and milestone payments.
- The company reported a negative EBITDA of EUR17.7 million, driven by reduced revenues and increased R&D and SG&A expenses.
- There is ongoing legal uncertainty with Regeneron regarding the Eylea biosimilar, which could impact market entry timelines.
- Market adoption of the FYB201 biosimilar has been slower in some regions, prompting plans to introduce a prefilled syringe to boost uptake.
- The company's financial guidance for 2025 is challenging due to uncertainties in product commercialization and market dynamics.
Thank you very much for the kind introduction. Dear ladies and gentlemen, warm welcome on behalf of the complete Formycon Management Board to our earnings call. We appreciate your interest. Those ones who have read potentially our press release earlier this morning can already confirm that we are looking at encouraging numbers for the first nine months in this year.
In summary, we have a very strong operational performance with multiple highlights, and we are also looking at robust financial key indicator. Enno Spinner, our CFO, and me will be happy to guide you through the details of the nine months performance.
As always, in those settings, we want to remind you that our presentation contains forward-looking statements, which are based on our current assumptions and might be subject to change if unexpected risks or uncertainties materialize. There's still too many patients with severe diseases that are heavily underserved with biologics. And it's our mission as Formycon to change that. and to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
